BrainAurora Medical Technology Limited (6681) Announces Independent Non-Executive Director Resignation, New Board Appointment, and CEO Designation

Bulletin Express11-18

BrainAurora Medical Technology Limited (stock code: 6681) announced that Independent Non-Executive Director Li Yuezhong resigned effective November 18, 2025, citing other work commitments. According to the announcement, there is no disagreement with the board, and no matters require further attention.

Mr. Tu Lei, aged 44, has been appointed as Independent Non-Executive Director with effect from November 18, 2025. He possesses extensive experience in corporate finance and management, having previously served in senior roles at Standard Chartered Bank, Credit Suisse Group AG, and UBS Group. His remuneration is set at HK$300,000 per year.

Board committee changes include Mr. Tu’s assumption of the Remuneration Committee chairmanship and membership in both the Audit Committee and the Nomination Committee. Two other members, Ms. Li Mingqiu and Mr. Lam Yiu Por, have also joined the Nomination Committee.

In addition, the announcement states that, effective immediately, Chief Technology Officer and Chief Operating Officer Mr. Cai Longjun, aged 42, has been appointed as Chief Executive Officer. Mr. Cai’s professional background features over 15 years in computer science, including key positions at major global technology enterprises. The annual service fee for his role as CEO is RMB1,132,800 per year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment